Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis

Leonardo Callea, Marco Arese, Alberto Orlandini, Cesare Bargnani, Alberto Priori, Federico Bussolino

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Platelet-activating factor (PAF) is a phospholipid mediator of inflammation with a wide range of biological activities, including the alteration of barrier function of endothelium. A biological assay combined with high pressure liquid chromatography-tandem mass spectrometry showed that plasma and cerebral spinal fluid (CSF) PAF levels in 20 patients with relapsing/remitting or secondary progressive multiple sclerosis (MS) studied by magnetic resonance imaging (MRI) were significantly higher than in healthy controls (plasma: 3.29 ± 4.52 vs. 0.48 ± 0.36 ng/ml, p <0.002; CSF: 4.95 ± 6.22 ng/ml vs. 0.01 ± 0.04 ng/ml, p <0.0001). Values were also significantly higher in relapsing/remitting than in secondary progressive (plasma: 5.10 ± 4.97 vs. 0.52 ± 0.85 ng/ml, p <0.005; CSF: 8.59 ± 6.39 vs. 0.55 ± 0.68 ng/ml, p <0.002). It was also found that both plasma (R 2: 0.65) and CSF (R 2: 0.72) levels were correlated with the MRI number of gadolinium enhancing lesions, which are markers of blood-brain barrier (BBB) injury, whereas their peaks were not correlated with the MRI number of white matter lesions, nor with the expanded disability status score (EDSS) according to Kurtze [Kurtze, J.F., 1983. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 33, 1444- 1452]. Both plasma and CSF in patients with relapsing/remitting MS and marked gadolinium enhancement contained the two major molecular species of PAF: 1- 0-hexadecyl- (C16:O) and 1-0-octadecyl-sn-glycero-3-phosphocholine (C18:O). The ratio of the two molecular species was different in the two biological fluids, being PAF C18:0 more abundant in CSF and PAF C16:0 in plasma, indicating a different cellular origin of PAF or different enzymatic processing. These findings suggest that PAF is a significant mediator of BBB injury in the early stages of MS, rather than a marker of its progression and severity.

Original languageEnglish
Pages (from-to)212-221
Number of pages10
JournalJournal of Neuroimmunology
Volume94
Issue number1-2
DOIs
Publication statusPublished - Feb 1 1999

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Platelet Activating Factor
Magnetic Resonance Imaging
Gadolinium
Blood-Brain Barrier
Brain Injuries
Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Inflammation Mediators
Phosphorylcholine
Neurology
Tandem Mass Spectrometry
Biological Assay
Endothelium
Phospholipids
High Pressure Liquid Chromatography

Keywords

  • Blood-brain barrier
  • Multiple sclerosis
  • PAF

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. / Callea, Leonardo; Arese, Marco; Orlandini, Alberto; Bargnani, Cesare; Priori, Alberto; Bussolino, Federico.

In: Journal of Neuroimmunology, Vol. 94, No. 1-2, 01.02.1999, p. 212-221.

Research output: Contribution to journalArticle

@article{d9af92a64d9142a8aaa3441faede12fb,
title = "Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis",
abstract = "Platelet-activating factor (PAF) is a phospholipid mediator of inflammation with a wide range of biological activities, including the alteration of barrier function of endothelium. A biological assay combined with high pressure liquid chromatography-tandem mass spectrometry showed that plasma and cerebral spinal fluid (CSF) PAF levels in 20 patients with relapsing/remitting or secondary progressive multiple sclerosis (MS) studied by magnetic resonance imaging (MRI) were significantly higher than in healthy controls (plasma: 3.29 ± 4.52 vs. 0.48 ± 0.36 ng/ml, p <0.002; CSF: 4.95 ± 6.22 ng/ml vs. 0.01 ± 0.04 ng/ml, p <0.0001). Values were also significantly higher in relapsing/remitting than in secondary progressive (plasma: 5.10 ± 4.97 vs. 0.52 ± 0.85 ng/ml, p <0.005; CSF: 8.59 ± 6.39 vs. 0.55 ± 0.68 ng/ml, p <0.002). It was also found that both plasma (R 2: 0.65) and CSF (R 2: 0.72) levels were correlated with the MRI number of gadolinium enhancing lesions, which are markers of blood-brain barrier (BBB) injury, whereas their peaks were not correlated with the MRI number of white matter lesions, nor with the expanded disability status score (EDSS) according to Kurtze [Kurtze, J.F., 1983. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 33, 1444- 1452]. Both plasma and CSF in patients with relapsing/remitting MS and marked gadolinium enhancement contained the two major molecular species of PAF: 1- 0-hexadecyl- (C16:O) and 1-0-octadecyl-sn-glycero-3-phosphocholine (C18:O). The ratio of the two molecular species was different in the two biological fluids, being PAF C18:0 more abundant in CSF and PAF C16:0 in plasma, indicating a different cellular origin of PAF or different enzymatic processing. These findings suggest that PAF is a significant mediator of BBB injury in the early stages of MS, rather than a marker of its progression and severity.",
keywords = "Blood-brain barrier, Multiple sclerosis, PAF",
author = "Leonardo Callea and Marco Arese and Alberto Orlandini and Cesare Bargnani and Alberto Priori and Federico Bussolino",
year = "1999",
month = "2",
day = "1",
doi = "10.1016/S0165-5728(98)00246-X",
language = "English",
volume = "94",
pages = "212--221",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis

AU - Callea, Leonardo

AU - Arese, Marco

AU - Orlandini, Alberto

AU - Bargnani, Cesare

AU - Priori, Alberto

AU - Bussolino, Federico

PY - 1999/2/1

Y1 - 1999/2/1

N2 - Platelet-activating factor (PAF) is a phospholipid mediator of inflammation with a wide range of biological activities, including the alteration of barrier function of endothelium. A biological assay combined with high pressure liquid chromatography-tandem mass spectrometry showed that plasma and cerebral spinal fluid (CSF) PAF levels in 20 patients with relapsing/remitting or secondary progressive multiple sclerosis (MS) studied by magnetic resonance imaging (MRI) were significantly higher than in healthy controls (plasma: 3.29 ± 4.52 vs. 0.48 ± 0.36 ng/ml, p <0.002; CSF: 4.95 ± 6.22 ng/ml vs. 0.01 ± 0.04 ng/ml, p <0.0001). Values were also significantly higher in relapsing/remitting than in secondary progressive (plasma: 5.10 ± 4.97 vs. 0.52 ± 0.85 ng/ml, p <0.005; CSF: 8.59 ± 6.39 vs. 0.55 ± 0.68 ng/ml, p <0.002). It was also found that both plasma (R 2: 0.65) and CSF (R 2: 0.72) levels were correlated with the MRI number of gadolinium enhancing lesions, which are markers of blood-brain barrier (BBB) injury, whereas their peaks were not correlated with the MRI number of white matter lesions, nor with the expanded disability status score (EDSS) according to Kurtze [Kurtze, J.F., 1983. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 33, 1444- 1452]. Both plasma and CSF in patients with relapsing/remitting MS and marked gadolinium enhancement contained the two major molecular species of PAF: 1- 0-hexadecyl- (C16:O) and 1-0-octadecyl-sn-glycero-3-phosphocholine (C18:O). The ratio of the two molecular species was different in the two biological fluids, being PAF C18:0 more abundant in CSF and PAF C16:0 in plasma, indicating a different cellular origin of PAF or different enzymatic processing. These findings suggest that PAF is a significant mediator of BBB injury in the early stages of MS, rather than a marker of its progression and severity.

AB - Platelet-activating factor (PAF) is a phospholipid mediator of inflammation with a wide range of biological activities, including the alteration of barrier function of endothelium. A biological assay combined with high pressure liquid chromatography-tandem mass spectrometry showed that plasma and cerebral spinal fluid (CSF) PAF levels in 20 patients with relapsing/remitting or secondary progressive multiple sclerosis (MS) studied by magnetic resonance imaging (MRI) were significantly higher than in healthy controls (plasma: 3.29 ± 4.52 vs. 0.48 ± 0.36 ng/ml, p <0.002; CSF: 4.95 ± 6.22 ng/ml vs. 0.01 ± 0.04 ng/ml, p <0.0001). Values were also significantly higher in relapsing/remitting than in secondary progressive (plasma: 5.10 ± 4.97 vs. 0.52 ± 0.85 ng/ml, p <0.005; CSF: 8.59 ± 6.39 vs. 0.55 ± 0.68 ng/ml, p <0.002). It was also found that both plasma (R 2: 0.65) and CSF (R 2: 0.72) levels were correlated with the MRI number of gadolinium enhancing lesions, which are markers of blood-brain barrier (BBB) injury, whereas their peaks were not correlated with the MRI number of white matter lesions, nor with the expanded disability status score (EDSS) according to Kurtze [Kurtze, J.F., 1983. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 33, 1444- 1452]. Both plasma and CSF in patients with relapsing/remitting MS and marked gadolinium enhancement contained the two major molecular species of PAF: 1- 0-hexadecyl- (C16:O) and 1-0-octadecyl-sn-glycero-3-phosphocholine (C18:O). The ratio of the two molecular species was different in the two biological fluids, being PAF C18:0 more abundant in CSF and PAF C16:0 in plasma, indicating a different cellular origin of PAF or different enzymatic processing. These findings suggest that PAF is a significant mediator of BBB injury in the early stages of MS, rather than a marker of its progression and severity.

KW - Blood-brain barrier

KW - Multiple sclerosis

KW - PAF

UR - http://www.scopus.com/inward/record.url?scp=0033081106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033081106&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(98)00246-X

DO - 10.1016/S0165-5728(98)00246-X

M3 - Article

VL - 94

SP - 212

EP - 221

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -